Co-Authors
This is a "connection" page, showing publications co-authored by Jieni Li and Rajender Aparasu.
Connection Strength
7.067
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.975
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
Score: 0.974
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
Score: 0.964
-
Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. Explor Res Clin Soc Pharm. 2023 Sep; 11:100307.
Score: 0.887
-
Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
Score: 0.827
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
Score: 0.807
-
Risk of Antipsychotic Initiation Among Older Dementia Patients Initiating Cholinesterase Inhibitors. Drug Healthc Patient Saf. 2025; 17:75-85.
Score: 0.249
-
Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
Score: 0.244
-
Risk of antimuscarinic initiation with cholinesterase inhibitor use in Alzheimer's disease. Arch Gerontol Geriatr. 2025 Jan; 128:105629.
Score: 0.241
-
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
Score: 0.232
-
Application of machine learning in predicting survival outcomes involving real-world data: a scoping review. BMC Med Res Methodol. 2023 11 13; 23(1):268.
Score: 0.227
-
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
Score: 0.220
-
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data. J Manag Care Spec Pharm. 2023 May; 29(5):480-489.
Score: 0.219